Khorana Score

:

Practical-Haemostasis.com
A Practical Guide to Haemostasis

The Khorana Score

Introduction

The Khorana Score was the first risk assessment algorithm to stratify a cancer patients' risk of VTED and has been validated in a number of retrospective and prospective studies. The study was a multicentre prospective observational study of 2701 cancer outpatients receiving chemotherapy and the risk model was subsequently validated in an independent cohort of 1365 patients from the same study.
The study identified five predictive variables from a multivariate model and these are summarised below:

The KHORANA Score:

Score

[Max Score 6 Points]

Interpretation
Score	VTE Risk Category
≥ 3 Points	High risk score VTED Rate 7.1%
1- 2 Points	Intermediate risk score VTED Rate 1.8%
0 Points	Low risk score VTED Rate 0.8%

Navigation

Screening Tests

Introduction & Bleeding Questionnaires
Prothrombin Time [PT]
Activated Partial Thromboplastin Time [APTT]
Thrombin Time [TT]
Fibrinogen Assays
Summary

Factor & Inhibitor Assays

Factor Assays
Introduction
1-Stage PT-based Factor Assays
1-Stage APTT-based Factor Assays
1-Stage RVV-based Factor X Assay
2-Stage Factor VIII Assay
Chromogenic FVIII and FIX Assays
Factor XIII Assays
Monitoring Concentrates and non-factor Therapies
Inhibitor Assays
Introduction
Inhibitor Screening Tests
Bethesda Assay
Nijmegen modification
VWF Inhibitor Assays
Von Willebrand Factor [VWF] Assays
Introduction
Immunological Assays
FVIII Binding Assay
VWF Collagen Binding Assay
VWF Ristocetin Cofactor Assay
VWF Epitope-Specific Assays
RIPA Assay
VWF Multimer Analysis
VWF Propeptide [VWFpp] Assay
VWF Inhibitor Assays

Platelet Function Testing

Introduction
Light Transmission Aggregometry [LTA]
Impedance Platelet Aggregometry
PFA-100/200
VerifyNow Assay
Global Thrombosis Test
Platelet Nucleotide Assays
Flow Cytometry
Platelet Procoagulant Assays

Thrombophilia Testing

Thrombophilia Testing - Introduction
Antithrombin Assays
Protein C Assays
Protein S Assays
APCr Assays
Protein C Global Assay
Homocysteine
Antiphospholipid Assays
Introduction
Dilute Russell Viper Venom Time [dRVVT]
Kaolin Clotting Time [KCT]
Silica Clotting Time [SCT]
Taipan Venom Time
Taipan:Ecarin Ratio
Textarin:Ecarin Ratio
Dilute Thromboplastin Inhibition Test [DTI]
Anticardiolipin & Anti-β₂ GPI Assays

Fibrinolytic Assays

Introduction
D-Dimer Assays
FDP Assays
Euglobulin Clot Lysis Time [ECLT]
Alpha2-PI Assays
Plasminogen Assays
PAI-1 Assays
t-PA Assays
TAFI Assays
u-PA Assays
Venous Occlusion Test
Global Assays of Fibrinolysis
GFC Assay
CloFAL Assay
OHP Assay
CIP Assay

Genetic Tests

Introduction
Bayesian Risk Analysis
Pascal's Triangle
Linkage Analysis
Mutational Analysis
Hardy Weinberg Principle
Prothrombin F2 G20201A Mutation
Factor V Leiden Mutation

Miscellaneous Tests

Activated Clotting Time [ACT]
Anti-Xa Assays
ADAMTS13 Assays
HIT and HIT Assays
Ecarin Clotting Time [ECT]
Protamine Sulphate Neutralisation Test
Prothrombinase-induced Clotting Test
Reptilase Time
Stypven Time
ISI and INR
Bleeding Time [BT]
Heparin Cofactor II [HCII] Assays
Prothrombin F1+2 Assays

Global Tests of Haemostasis

Introduction to Global Assays
ETP Assays
TEG and ROTEM Analyses
Global Thrombosis Test
ReoRox G2 Assay
Global Assays of Fibrinolysis
GFC Assay
CloFAL Assay
OHP Assay
CIP Assay

Quality Assurance

An introduction to Quality Assurance in Haemostasis
Pre-Analytical Variables

Risk Assessment Algorithms

Risk Assessment Algorithms: Introduction
Atrial Fibrillation and Ischaemic Stroke
Atrial Fibrillation and the Risk of Bleeding
Anti-Phospholipid Syndrome [APS]
Bleeding Assessment
DIC Assessment
Heparin-induced Thrombocytopaenia [HIT]
Post-Thrombotic Syndrome
Thrombotic Microangiopathies [TMAs]
Upper Extremity Thromboses
VTED Risk In Hospitalised Patients
VTED - Diagnosis
VTED - Assessing Bleeding Risk
VTED - Risk of Recurrence
VTED and Cancer

Useful Information

Paediatric Reference Ranges
Haemostatic Drugs
DOACs and Laboratory Tests
Snake Venoms in Haemostasis
Vitamin K & Haemostasis

Home Page

Data Interpretation App

EMBOLUS - THE APP

Miscellaneous

CONTACT US
SITE MAP
PRIVACY POLICY

Comments

NOTE: Whilst we have done our utmost to ensure the accuracy of the data in this section, users should access the original publications.

All information contained in this section of Practical-Haemostasis.com is provided for educational purposes only. This information should not be used for the diagnosis or treatment of any health problem or disease.

The user of Practical-Haemostasis.com, assumes sole responsibility for any decisions made or actions taken based on the information contained herein.

1. European Society for Medical Oncology - Click HERE to access management of VTE in Cancer Patients.

LINKS & References

1. Khorana AA, Kuderer NM, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902-7.

2. Angelini D and Khorana AA. Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease. Semin Thromb Hemost. 2017; 43: 469-78.

3. Riondino S, Ferroni P, et al. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers (Basel). 2019; 11.

4. Kearon C, Akl EA, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149: 315-52.

5. Key NS, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019: JCO1901461.

6. Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(2):173-90.

7. Khorana AA, Cohen AT, Carrier M, et al. Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO. 2020;5(6):e000948.

8. Candeloro M, Guman NAM, Kraaijpoel N, et al. Risk Assessment Models for Thrombosis and Anticoagulant-Related Bleeding in Ambulatory Cancer Patients. Semin Thromb Hemost. 2021;47(8):972-81.